Polymyalgia rheumatica and its mimics
Follow a patient from the first episode of shoulder stiffness to a difficult taper. Open the existing cases, compare imaging findings and review the evidence at the point of decision.
In this guide
Mimics and imaging
Suspected GCA
Treatment and follow-up
Clinical practice
Start here
Professional Essentials · OpenFind a mimic by presentation
Recognising mimics
Persistent peripheral synovitis, objective weakness or pain confined to one shoulder changes the examination and the choice of investigation. A glucocorticoid response alone does not establish PMR.
Focal shoulder pain and radiographic osteoarthritis
Review the glenohumeral joint space and marginal osteophytes in Case 004. Decide whether the image fits the distribution of pain.
Knee chondrocalcinosis and the CPPD differential
Case 015 shows advanced osteoarthritis and probable meniscal chondrocalcinosis. Correlate the radiographic findings with the joint examination and, where appropriate, synovial fluid analysis.
When to suspect GCA
New transient or persistent visual loss or diplopia in suspected GCA warrants immediate assessment. Strong clinical suspicion calls for immediate treatment while diagnostic testing is arranged.
Urgent visual symptoms · open GCA guide Full emergency quick card · Professional access
Clinical decisions
High Stakes Carousel · 10 PMR modules
Seven formats in each module: odd one out, matching, swipe, sequence, number, trap and a final duel. Explore red flags, assessment, treatment, safety and research.
The Wager · 10 PMR modules
Practice clinical decisions from the first assessment through relapse, steroid-sparing treatment and new research. Eight questions are drawn from a pool of twelve in each module.
A Polymyalgia That Did Not Behave
Twelve encounters over thirty months. Reassess the working diagnosis when the course changes.
Symptoms that would not settle on 15 mg
Work through six decisions in the Crucible case, including when an incomplete response should prompt consideration of large-vessel GCA.
Vasculitis II · Clinical Rounds
Assess threatened vision, vascular imaging and follow-up in GCA, PMR and Takayasu arteritis.
Treatment and research
November 9 update to the October clinical review
The October BSR guideline recommends starting prednisolone at 12.5–15 mg/day for newly diagnosed PMR, increasing to 25 mg/day if needed for symptom control. In a small randomized trial of recently diagnosed PMR, methotrexate 25 mg/week increased glucocorticoid-free remission at week 52 from 46% with placebo to 80% with methotrexate. The analysis included 58 participants. BSR guideline · Methotrexate trial
New international imaging recommendations reserve vascular imaging for clinical suspicion of GCA. Evidence is insufficient to support systematic screening for subclinical vasculitis in otherwise asymptomatic patients with PMR. PMR imaging recommendations
In October 2026, the European Commission approved secukinumab for adults with PMR who have an inadequate response to glucocorticoids or relapse during taper. In the United States, secukinumab is approved for adults with PMR when corticosteroids have not worked well enough or when the patient cannot tolerate a corticosteroid taper. EU prescribing information · US prescribing information
The second year of prednisone
Use the clinical review for relapse, steroid-sparing treatment and monitoring when CRP is suppressed. Read current prescribing information for regional indications.
How JAK/STAT signalling works
See how a cytokine signal reaches the nucleus. The animation explains the molecular target. For PMR-specific outcomes, read BACHELOR and the JADORE-BARI study record.
Bone remodelling and vertebral fragility
The film illustrates bone resorption and formation and how a vertebra can fracture. For glucocorticoid-associated fracture risk, use the ACR guideline alongside the film.